Please assess the completion status of the following clinical trial:

Trial Title: A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Part A: Overtly healthy postmenopausal (PMP) females~* Part B: PMP women who are currently taking oral bisphosphonates for prevention or treatment of osteoporosis~* Have a body mass index (BMI) at screening of 19.0 to 35.0 kilogram per square meter (kg/m\^2)~Exclusion Criteria:~* Have known allergies to blosozumab, its constituents, or related compounds~* Have an abnormality in the 12-lead electrocardiogram (ECG)~* History of breast carcinoma~* Fracture of a long bone within 1 year of screening~* Have used teriparatide within 3 years prior to screening

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Blosozumab Formulation A (Type: EXPERIMENTAL): Part A. Blosozumab administered as 2 subcutaneous (SC) injections in week 1 followed by once weekly (QW) injections SC in weeks 2 to 6, followed by six week follow-up period.
- Blosozumab Formulation B (Type: EXPERIMENTAL): Part A. Blosozumab administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
- Placebo (Type: PLACEBO_COMPARATOR): Part A. Placebo administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
- Blosozumab (Part B) (Type: EXPERIMENTAL): Part B. Blosozumab formulation determined by Part A administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).